Citations

Clear

4 citation(s) found for "DiMeglio, Linda".

Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial
Grunberger, George , Weinstock, Ruth S. , Hirsch, Irl B. , DiMeglio, Linda A. , Philis‐Tsimikas, Athena , Kipnes, Mark, Liljenquist, David R., Brazg, Ronald, Kudva, Yogish C. , Buckingham, Bruce A. , Carlson, Anders L. , Criego, Amy , Christiansen, Mark P., Kaiserman, Kevin B. , Forlenza, Gregory P. , Bode, Bruce W. , Slover, Robert H., Keiter, Ashleigh , Ling, Chenxiao , Marinos, Briggitte, Cordero, Toni L. , Shin, John , Lee, Scott W., Rhinehart, Andrew S., Group, for the Adult and Pediatric MiniMed™ HCL Outcomes 6-month RCT: HCL versus CSII Control Study, Downs, Ashleigh, Lange, Samantha , Jost, Emily , KARAMI, ANGELA J., Hamill, Donna, Simha, Vinaya , Desjardins, Donna, Spitzer, Shelly McCrady, Reid, Corey, Kaur, Ravinderjeet, Malone, Halvorson, Mary, Ekhlaspour, Laya , Weir, Christine, Casaubon, Luis, Ang, Lynn , Plunkett, Cindy, Recklein, Carol, Clifton, Mary Jane, Weinstock, Ruth S , Hirsch, Irl B , Kudva, Yogish C. , McGill, Janet B. , Forlenza, Gregory P , Cordero, Toni L , Vigersky, Robert A , Philis-Tsimikas, Athena , Buckingham, Bruce , DiMeglio, Linda , Garg, Satish K. , Lawson, Margaret L. , Pop‐Busui, Rodica , Griffin, Kurt , Vigersky, Robert A. , Group, for the Adult and Pediatric MiniMed™ HCL Outcomes 6-month RCT: HCL versus CSII Control Study, Kaur, Ravinder Jeet , Malone, Stout, Kara Mizokami , Plunkett, Cindy, Williams, Brittany

Mayo Clinic

Diabetes Technology & Therapeutics | December 6, 2022 | Volume: 25 | Issue: 1 | Pages: 1-12

10.1089/dia.2022.0421 | PMID 36472543 Get It

Editorial Cycles and Continuity of Diabetes Care
Riddle, Matthew C. , Aroda, with and on behalf of Associate Editors Vanita, Bakris, George L. , Blonde, Lawrence , Boulton, Andrew J.M. , Castle, Jessica R. , DiMeglio, Linda A. , Gonder‐Frederick, Linda , Hu, Frank B. , Kahn, Steven E. , Kaul, Sanjay , Moses, Robert G. , Rosenstock, Julio , Selvin, Elizabeth , Selvin, Elizabeth , Hu, Frank B. , Bakris, George , Castle, Jessica R , DiMeglio, Linda , Hu, Frank , Kahn, Steven , Moses, Robert G , Rich, Stephen S , Rosenstock, Julio , Selvin, Elizabeth , Vella, Adrian , Wylie‐Rosett, Judith , Aroda, with and on behalf of Associate Editors Vanita, Rich, Stephen S. , Vella, Adrian

Mayo Clinic

Diabetes Care | July 7, 2022 | Volume: 45 | Issue: 7 | Pages: 1493-1494

10.2337/dci22-0020 | PMID 35796770 Get It

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Sims, Emily K. , Bundy, Brian N. , Stier, Kenneth , Serti, Elisavet , Lim, Noha , Long, S. Alice , Geyer, Susan, Moran, Antoinette , Greenbaum, Carla J. , Evans‐Molina, Carmella , Group, Type 1 Diabetes TrialNet Study, DiMeglio, Linda A. , Gitelman, Stephen E. , Gottlieb, Peter A. , Marks, Jennifer B. , Moore, Wayne D. , Rodriguez, Henry , Russell, William E. , Schatz, Desmond , Wherrett, Diane K. , Ziegler, Anette‐Gabriele , Herold, Kevan C , DiMeglio, Linda , Group, Type 1 Diabetes TrialNet Study, Moore, Wayne, Tsalikian, Eva

Mayo Clinic

Science Translational Medicine | March 3, 2021 | Volume: 13 | Issue: 583 | Pages: No page available

10.1126/scitranslmed.abc8980 | PMID 33658358 Get It

Teplizumab treatment of nondiabetic relatives at high risk for T1D induces partially exhausted CD8 + T cells and improves beta cell function.
Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate Supplementation
Eswarakumar, Abigail S. , Nina, S. , Ward, Leanne M. , Wasserman, Halley , DiMeglio, Linda A. , Gagné, Julie, Cody, Declan, Zimakas, Paul, Topor, Lisa Swartz , Agrawal, Sungeeta , Calabria, Andrew C. , Tebben, Peter J. , Faircloth, Ruth, Gordon, Rebecca J. , Casey, Linda , Tebben, Peter, Carpenter, Thomas O , DiMeglio, Linda , Tebben, Peter , Backeljauw, Philippe Ferdinand , Weber, David R. , Imel, Erik Allen

Mayo Clinic

Clinical Pediatrics | July 15, 2020 | Volume: 59 | Issue: 12 | Pages: 1080-1085

10.1177/0009922820941097 | PMID 32666808 Get It

In this article, we describe the long-term outcomes of children who were previously reported to have developed hypophosphatemic bone disease in association with elemental formula use. An extended chart review allowed for an updated report of 34 children with regard to severity/duration of bone disease, extent of recovery, and time to correction using radiology reports and biochemical data. After implementation of formula change and/or phosphate supplementation, we found that serum phosphorus concentration increased and serum alkaline phosphatase activity decreased in all patients, normalizing by 6.6 ± 4.0 (mean ± SD) months following diagnosis. The decrease in serum alkaline phosphatase from diagnosis to the time of correction was moderately correlated with the concurrent increase in serum phosphorus ( R = 0.48, P < .05). Age at diagnosis significantly correlated with time to resolution ( R = 0.51, P = .01). This study supports the earlier report that bone disease associated with hypophosphatemia during elemental formula use responds to formula change and/or phosphate supplementation.